Thyrotropin-releasing hormone (TRH) is a hypothalamic tripeptide that serves as the primary regulator of TSH secretion from the pituitary gland but is also widely distributed throughout the CNS as an independent neuromodulator affecting dopaminergic, cholinergic, and serotonergic neurotransmitter systems independent of its thyroid axis role. Beyond endocrine function, centrally administered TRH exerts arousal-promoting effects and has been shown in preclinical models to prevent depletion of cortical acetylcholine and monoamines following brain injury, suggesting a neuroprotective neuromodulatory role. Controlled human research has demonstrated that TRH attenuates scopolamine-induced memory impairment, consistent with its proposed role in potentiating cholinergic signaling and providing direct evidence for central cognitive effects of the parent compound. TRH is used clinically as a diagnostic agent (protirelin) for thyroid function testing; as a cognitive or neuroprotective agent it remains investigational, with no approved indication for these uses and human evidence limited to small mechanistic studies. TRH in neuroendocrinology and nootropic research Beyond its role as a hypophysiotropic releasing factor, TRH functions as a neuromodulator throughout the CNS. TRH receptors (TRH-R1 and TRH-R2) are expressed in the cerebral cortex, hippocampus, limbic system, and spinal cord, mediating effects on arousal, mood, and locomotor activity independent of the pituitary-thyroid axis. Animal studies document TRH's analeptic properties — the peptide can rapidly reverse sedation from barbiturates, ethanol, and opioids, suggesting a direct CNS excitatory role. This arousal-promoting effect has attracted research interest in fatigue, cognitive impairment, and as an emergency reversal agent in overdose contexts, though clinical translation has been limited by TRH's very short half-life (approximately 5 minutes in plasma due to rapid enzymatic degradation). Taltirelin (TA-0910), a more metabolically stable TRH analogue, is approved in Japan for spinocerebellar degeneration — the only approved clinical application in this research space. The TRH stimulation test (200–500mcg IV bolus with serial TSH/prolactin sampling) has been used diagnostically, though modern ultrasensitive TSH assays have largely replaced it. Exogenous TRH for nootropic or energy applications is available as a research peptide; intranasal delivery to bypass peripheral degradation has been explored in preclinical work.